Acute Respiratory Distress Syndrome (ARDS) is a life-threatening severe orphan disease in which the air sacs present in alveoli are filled with fluid and lower the amount of oxygen in the blood. Thus, enough oxygen is not supplied to the body. Inflammation may occur throughout the lungs.

1. MARKET INSIGHTS,
EPIDEMIOLOGY
&
MARKET FORECAST-2027
ACUTE RESPIRATORY
DISTRESS SYNDROME
(ARDS)

2.  Acute Respiratory Distress Syndrome (ARDS) is a life-
threatening severe orphan disease in which the air sacs
present in alveoli are filled with fluid and lower the
amount of oxygen in blood. Thus, enough oxygen is not
supplied to the body. Inflammation may occur
throughout the lungs.
 ARDS is also classified on the basis of severity of disease
as Mild ARDS, Moderate ARDS and Severe ARDS by
Berlin definition. It is generally characterized into three
stages such as exudative stage, fibro proliferative (or
proliferative) stage, resolution and recovery stage.
2
DelveInsight © 2018 | All rights reserved
ACUTE RESPIRATORY DISTRESS SYNDROME

3. 3
DelveInsight © 2018 | All rights reserved
EPIDEMIOLOGY INSIGHTS
DelveInsight estimates
ARDS incidence has varied
from 1.3 to 22 per 100,000
person years.
Cross-sectional studies
demonstrate that patients
with ARDS represent
approximately 5% of
hospitalized, mechanically
ventilated patients.
Mild ARDS represents
only 25% of patients
with ARDS,
approximately 75% of
patients are reported
with moderate or
severe ARDS.
ARDS occurrence varies
consistently, ranging from 10.6
per 100,000 person-years in
Finland, to 17.9 per 100,000
person-years in Scandinavia, to
25.5 per 100,000 person-years
in Spain.
1
2
3
4

4. Extensive research and
development activities of
pharmaceutical companies are
being carried out for developing the
therapies for ARDS along with the
emerging therapies in the pipeline
Market Size of ARDS in
the 7MM was found to be
XXX in 2016
MARKET INSIGHTS
Owing to the launch of
upcoming therapies, the
market size shall increase
significantly during forecast
period (2018-2027)
There are many potential
pipeline drugs expected to enter
ARDS market by XXXX and
subsequent years.
Expected launch of BioMark
Pharmaceuticals’ BIO-11006,
Techpool, Bio-Pharma‘s Ulinastatin
and other therapies shall impact
the market size of ARDS
ARDS
4
DelveInsight © 2018 | All rights reserved

5. 5
DelveInsight © 2018 | All rights reserved
03
02
01
K
E
Y
P
L
A
Y
E
R
S
Faron Pharmaceuticals
Techpool Bio-Pharma
BioMarck Pharmaceuticals

6. 6
DelveInsight © 2018 | All rights reserved
COMPLETE INFORMATION
For complete information please click below
Or
Write to us at
info@delveinsight.com
CLICK HERE

7. 01 02 03
ABOUT DELVEINSIGHT 7
DelveInsight, market research
and consulting firm, provides
end to end comprehensive
solutions to the Life Science
Industry.
We help our customers in best
decision making through our
expertise in research & analysis
and comes out with unmatched
data & forecasts
Vision
“Insight across the value
chain”
to help organizations
make
important business
decisions
through the use and
analysis of actionable
market intelligence
Mission
 To be the most trusted
marketing research
firm & business
consulting firm
worldwide.
 To be a renowned and
premier data driven
solution providers
among Pharma &
Biotech companies.
DelveInsight © 2018 | All rights reserved

8. 8
DelveInsight © 2018 | All rights reserved
SERVICE OFFERINGS AT DELVEINSIGHT
Comprehensive solution for strategic business decisions
• Trends Analysis
• Physicians & Patients Perception
• KOLs
• Market Size
• Market Dynamics
• Market Assessment
Access over 3000+ Reports
• API
• Market & Pipeline
• Indication & Epidemiology
• Drug Sales Forecast
• Indication Forecast
• Late Stage Pipeline Analysis
• Asset Prioritization
• Brand Optimization
• Portfolio Expansion
Opportunity Assessment for
• Licensing
• Market Access
• Partnership
• Competitive landscape
• Clinical Trials
• Therapeutic Assessment
• Primary Analytics
• News-Letters
• Conference Tracking
• Clinical Trials Tracking
Market
Intelligence
Consulting
SociAlytics
Pipeline
Forecasting

9. Add a Slide
Title - 5
Contact Us:
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight